Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
September 03, 2020 07:05 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in September

LEXINGTON, Mass. and AMSTERDAM, Sept. 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
August 26, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development

LEXINGTON, Mass. and AMSTERDAM, Aug. 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
July 30, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress

~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~ ~ Completed First Patient Dosing in...
June 24, 2020 16:05 ET | Source: uniQure Inc.

uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy

~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...
June 19, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
June 17, 2020 16:05 ET | Source: uniQure Inc.

uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors

~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
June 15, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Change for its 2020 Annual General Meeting of Shareholders

~ Virtual Meeting Only by Live Audio Webcast – No Physical Meeting Location ~ LEXINGTON, Mass. and AMSTERDAM, June 15, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE) announced today a...
May 14, 2020 07:00 ET | Source: uniQure Inc.

uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting

~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing Platform ~ ~ New Non-Human Primate Data Demonstrate Feasibility of...
April 29, 2020 07:00 ET | Source: uniQure Inc.

uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress

~ Completed Target Patient Dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B ~ ~ Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting ~ LEXINGTON, Mass....